Ling Y Yu

US Patent:

20120148598, Jun 14, 2012

Filed:

Dec 1, 2011

Appl. No.:

13/309490

Inventors:

Soldano Ferrone - Pittsburgh PA, US
Xinhui Wang - Pittsburgh PA, US
Elvira Favoino - Bari, IT
Ling Yu - Pittsburgh PA, US
Yangyang Wang - Pittsburgh PA, US

International Classification:

A61K 39/395
A61P 35/04
A61P 35/00

US Classification:

4241561

Abstract:

Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.

US Patent:

20130259873, Oct 3, 2013

Filed:

Dec 1, 2011

Appl. No.:

13/991136

Inventors:

Soldano Ferrone - Boston MA, US
Xinhui Wang - Boston MA, US
Elvira Favoino - Casamassima Bari, IT
Ling Yu - Pittsburgh PA, US
Yangyang Wang - Pittsburgh PA, US

International Classification:

A61K 39/395
A61K 31/437
A61K 45/06

US Classification:

4241561

Abstract:

Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds high molecular weight melanoma associated antigen (HMW-MAA), also known as CSPG4; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.

US Patent:

20160304840, Oct 20, 2016

Filed:

Oct 31, 2014

Appl. No.:

15/030185

Inventors:

- Ipswich MA, US
Fanfan Chen - Ipswich MA, US
Xianghui Li - Shanghai, CN
Ling Yu - Ipswich MA, US
Yanye Feng - Ipswich MA, US

Assignee:

New England Biolabs, Inc. - Ipswich MA

International Classification:

C12N 7/00
C12N 5/0793
C12N 5/077
C12N 5/071
A61K 35/39
A61L 27/38
A61K 35/35
A61K 35/32
A61K 35/30
C12N 5/074
A61K 35/545

Abstract:

Described herein is an inactivated viral particle comprising one or more transcription factor proteins packaged within the particle. A method for using the particle to make induced pluripotent stem cells is also provided.

US Patent:

20140234324, Aug 21, 2014

Filed:

May 2, 2014

Appl. No.:

14/268925

Inventors:

Soldano Ferrone - Boston MA, US
Xinhui Wang - Boston MA, US
Elvira Favoino - Casamassima, IT
Ling Yu - Pittsburgh PA, US
Yangyang Wang - Pittsburgh PA, US

Assignee:

University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA

International Classification:

C07K 16/18
A61K 45/06
A61K 39/395
A61K 31/437

US Classification:

4241391

Abstract:

Combinations of agents that have a synergistic effect for the treatment of a tumor are disclosed herein. These combinations of agents can be used to treat tumors, wherein the cells of the cancer express a mutated BRAF. Methods are disclosed for treating a subject diagnosed with a tumor that expresses a mutated BRAF. The methods include administering to the subject (1) a therapeutically effective amount of an antibody or antigen binding fragment thereof that specifically binds glucose regulated protein (GRP) 94; and (2) a therapeutically effective amount of a BRAF inhibitor. In some embodiments, the tumor is melanoma. In some embodiments the method includes selecting a subject with primary or secondary resistance to a BRAF inhibitor. In further embodiments, treating the tumor comprises decreasing the metastasis of the tumor. In additional embodiments, the BRAF inhibitor comprises PLX4032 or PLX4720.